BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Press Releases

  Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

  June 25, 2025

   · 

  5 min read
• Press Releases

  ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200

  June 25, 2025

   · 

  4 min read
• Press Releases

  Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

  June 25, 2025

   · 

  14 min read
• Press Releases

  Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

  June 25, 2025

   · 

  7 min read
• Press Releases

  Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

  June 25, 2025

   · 

  8 min read
• Press Releases

  Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

  June 25, 2025

   · 

  8 min read
• Press Releases

  Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

  June 25, 2025

   · 

  6 min read
• Press Releases

  Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

  June 25, 2025

   · 

  8 min read
• 

  Duchenne muscular dystrophy

  FDA Reviews Sarepta’s Elevidys After Second Patient Death

  The FDA is assessing the need for “further regulatory action” on Sarepta’s Duchenne muscular dystrophy gene therapy in the aftermath of two patient deaths, though the regulator has not yet specified what action this could be.

  June 25, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Collaboration

  Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera

  Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move forward with another protein degrader from the biotech, designed to target immune-mediated diseases.

  June 25, 2025

   · 

  2 min read

   · 

  Tristan Manalac